Active, not recruitingEarly Phase 1NCT06366672
Evaluating the Human Immune Response to the JYNNEOS Vaccine
Studying Human infection by orthopoxvirus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Philip Mudd, MD, PhDWashington University School of Medicine
- Intervention
- JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Washington University in Saint Louis School of Medicine Emergency Care and Research Core, St Louis, Missouri, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06366672 on ClinicalTrials.govOther trials for Human infection by orthopoxvirus
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07199569Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsBavarian Nordic
- RECRUITINGPHASE2NCT06839989An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE3NCT06844487Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRCJean-Pierre Van geertruyden
- RECRUITINGNCT06885853Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN VaccineAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06771479A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineShanghai Institute Of Biological Products
- ACTIVE NOT RECRUITINGPHASE2NCT06549530Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsBavarian Nordic
- RECRUITINGNANCT05627713Clinical and Biological Aspects of the MONKEYPOX DiseaseInstitut Pasteur